Seneschal Advisors’s Biogen BIIB Stock Holding History

Seneschal Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$433	Hold	2	–	–	﹤0.01%	434
2026 Q1	$367	Hold	2	–	–	﹤0.01%	431
2025 Q4	$352	Buy	+2	New	+$327	﹤0.01%	448

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Seneschal Advisors's BIIB Position: Q2 2026 in Review

Seneschal Advisors held its Biogen (BIIB) position steady in Q2 2026 at 2 shares worth $433. The position accounts for ﹤0.01% of the portfolio, ranked #434.

Seneschal Advisors first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Seneschal Advisors held 2 shares of Biogen worth $433 as of Q2 2026.
Seneschal Advisors left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Seneschal Advisors's portfolio in Q2 2026, its #434 holding.
Seneschal Advisors first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.